Abstract
Chronic kidney disease (CKD) is a widespread health problem in the world and anaemia of renal origin is a common problem. Anaemia associated with CKD covers significant risk for faster progression of chronic renal failure, decreased quality of life, and clinical manifestation of cardiovascular disease. The mainstay of anaemia treatment secondary to end-stage renal disease (ESRD) has become erythropoiesis stimulating agents (ESAs). More than 90 % of ESRD patients maintained on dialysis respond to traditional recombinant human erythropoietin (rHU EPO) or to EPO analogues, also called “biosimilars”. Iron deficiency often co-exists in dialysis patients and must be evaluated and treated to reduce ESA requirements. Partial, but not complete correction of renal anaemia is associated with improved outcomes in patients with CKD. The use of ESAs does carry risks such as hypertension, pure red cell aplasia, or cancer, and these agents need to be used judiciously.
Keywords: Chronic kidney disease, anaemia, erythropoiesis stimulating agents, pure red cell aplasia
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Volume: 8 Issue: 3
Author(s): Holger Schmid and Helmut Schiffl
Affiliation:
Keywords: Chronic kidney disease, anaemia, erythropoiesis stimulating agents, pure red cell aplasia
Abstract: Chronic kidney disease (CKD) is a widespread health problem in the world and anaemia of renal origin is a common problem. Anaemia associated with CKD covers significant risk for faster progression of chronic renal failure, decreased quality of life, and clinical manifestation of cardiovascular disease. The mainstay of anaemia treatment secondary to end-stage renal disease (ESRD) has become erythropoiesis stimulating agents (ESAs). More than 90 % of ESRD patients maintained on dialysis respond to traditional recombinant human erythropoietin (rHU EPO) or to EPO analogues, also called “biosimilars”. Iron deficiency often co-exists in dialysis patients and must be evaluated and treated to reduce ESA requirements. Partial, but not complete correction of renal anaemia is associated with improved outcomes in patients with CKD. The use of ESAs does carry risks such as hypertension, pure red cell aplasia, or cancer, and these agents need to be used judiciously.
Export Options
About this article
Cite this article as:
Schmid Holger and Schiffl Helmut, Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2010; 8 (3) . https://dx.doi.org/10.2174/187152510791698398
DOI https://dx.doi.org/10.2174/187152510791698398 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strain and Strain Rate Imaging by Echocardiography - Basic Concepts and Clinical Applicability
Current Cardiology Reviews Small RNAs Play Big Roles: MicroRNAs in Diabetic Wound Healing
Current Molecular Medicine Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
Current Clinical Pharmacology Nailfold Capillaroscopy – Its Role in Diagnosis and Differential Diagnosis of Microvascular Damage in Systemic Sclerosis
Current Rheumatology Reviews The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Cubosomes as Carriers for MRI Contrast Agents
Current Medicinal Chemistry Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Validation of Two High-Performance Liquid Chromatographic Methods for the Analysis of Nadolol and Propranolol Hydrochloride Following In Vitro Transdermal Diffusion Studies
Current Pharmaceutical Analysis Leflunomide, a Reversible Monoamine Oxidase Inhibitor
Central Nervous System Agents in Medicinal Chemistry Antioxidant Profile of Home Prepared <i>Taraxacum Officinale</i> Weber Ex Wigg Beverage
Current Nutraceuticals Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets